- Osiris Therapeutics (NASDAQ:OSIR) receives a deficiency letter from Nasdaq prompted by its failure to file its 2015 10-K on time. It has until May 16 to submit a plan to regain compliance. Last week, it announced that it would be unable to file its annual report on time due to accounting errors related to certain distributor contracts.
- Previously: Osiris unable to file 2015 annual report due to accounting errors; shares down 26% premarket (March 16)